DynamX Bioadaptor Outperforms Stents in Pooled Analysis
A pooled analysis of 2,885 patients found the bioadaptor reduced target lesion failure from six to 24 months compared with a drug-eluting stent.
Updated on Nov. 2, 2026 in Heart Disease
Elixir Medical presented a pooled analysis of its INFINITY-SWEDENHEART and BIOADAPTOR randomized trials at the Transcatheter Cardiovascular Therapeutics conference in San Diego. The analysis found the DynamX bioadaptor reduced target lesion failure compared with Medtronic's Resolute Onyx drug-eluting stent.
Why it matters
The results offer evidence on how a bioadaptor compares with a widely used drug-eluting stent for patients needing coronary intervention. Cardiologists and device makers will weigh the findings as they assess treatment options for blocked heart arteries.
The evidence is an individual patient data pooled analysis of two randomized trials covering 2,885 patients, comparing the DynamX bioadaptor with Medtronic's Resolute Onyx drug-eluting stent. Reduced target lesion failure was observed from six to 24 months, while the size of the effect and outcomes beyond 24 months remain unreported.
The players
Elixir Medical
Elixir Medical is a medical device company that develops the DynamX bioadaptor for treating coronary artery disease.
Medtronic
Medtronic is a multinational medical technology company that manufactures the Resolute Onyx drug-eluting stent used as the comparator in the analysis.
The details
Elixir Medical pooled individual patient data from its INFINITY-SWEDENHEART and BIOADAPTOR randomized trials for the analysis. The findings were presented at the Transcatheter Cardiovascular Therapeutics conference, held Oct. 31 to Nov. 3 in San Diego.
Timeline
Oct. 31 to Nov. 3: Transcatheter Cardiovascular Therapeutics conference held in San Diego, where the analysis was presented.
Six to 24 months after the procedure: Period in which the DynamX bioadaptor reduced target lesion failure compared with the drug-eluting stent.
Health Landscape
The pooled analysis builds on the BIOADAPTOR and INFINITY-SWEDENHEART randomized trials by combining their patient data into one comparison with a standard drug-eluting stent. It adds to the evidence base on whether bioadaptors can match or exceed the stents that have been the standard of care for coronary intervention.
For patients with blocked heart arteries, the findings bear on which stent type their cardiologist may recommend. Patients considering these devices can ask their care team how long-term outcomes compare with the options available to them.
The takeaway
The pooled data suggest the DynamX bioadaptor may reduce target lesion failure compared with a drug-eluting stent over the first two years. Patients should discuss device options with their cardiologist, who can weigh these findings against individual risk factors.
Further reading
For more on treatments for coronary artery disease, see Heart Disease.
Source note: This article includes information reported by Insights.
